Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Vancomycin-resistant Staphylococcus aureus (VRSA) can overcome the cost of antibiotic resistance and may threaten vancomycin’s clinical durability

PLoS Pathogens(2024)10.1371/journal.ppat.1012422Source: DataRank Database

Vancomycin-resistant Staphylococcus aureus (VRSA) can overcome the cost of antibiotic resistance and may threaten vancomycin’s clinical durability is a research paper published in PLoS Pathogens (2024). On theSindex it has a DataRank of 0. It has been cited 11 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access11 citations

Download PDF

Cite:

Linked data & code

bioproject

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 3.62)OA: goldTopics (45)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (2)

Erik S. Wright ORCID,Samuel E. Blechman

Live enrichment

PubMed:39207957 PMC:PMC11361437 OpenAlex:https://openalex.org/W4401993214

Division of Intramural Research, National Institute of Allergy and Infectious Diseases

Grant: 1R21 AI144769-01A1

Overcoming antibiotics of last resort: determining the role of compensatory mutations in promoting vancomycin resistance in Staphylococcus aureus

NIAID NIH HHS

Grant: R21 AI144769

FWCI

3.62

Citation Percentile

0.9%

Citation Trend

2025

2026

goldLicense: cc-by

journalhttps://doi.org/10.1371/journal.ppat.1012422

publisherhttps://doi.org/10.1371/journal.ppat.1012422

publisherhttps://dx.plos.org/10.1371/journal.ppat.1012422

repositoryhttps://pubmed.ncbi.nlm.nih.gov/39207957

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/11361437

Fields of Study

Antimicrobial Resistance in StaphylococcusBacterial Identification and Susceptibility TestingClostridium difficile and Clostridium perfringens research0301 basic medicine03 medical and health sciencesVancomycinAnti-Bacterial AgentsHumansStaphylococcal InfectionsVancomycin-Resistant Staphylococcus aureusVancomycin ResistanceMicrobial Sensitivity TestsBacterial ProteinsMutation

MeSH Terms

Vancomycin-Resistant Staphylococcus aureusAnti-Bacterial AgentsBacterial ProteinsHumansMicrobial Sensitivity TestsMutationStaphylococcal InfectionsVancomycinVancomycin Resistance

Keywords

VancomycinStaphylococcus aureusAntibioticsMicrobiologyAntibiotic resistanceMethicillin-resistant Staphylococcus aureusMedicineBacteriaBiologyQH301-705.5Vancomycin ResistanceMicrobial Sensitivity TestsRC581-607Staphylococcal InfectionsAnti-Bacterial AgentsVancomycin-Resistant Staphylococcus aureusBacterial ProteinsMutationHumansImmunologic diseases. AllergyBiology (General)Research Article

Sustainable Development Goals

SDG 3: 3. Good health

Vancomycin-resistant Staphylococcus aureus (VRSA) can overcome the cost of antibiotic resistance and may threaten vancomycin’s clinical durability

FAIR Checklist

Authors (2)

Funding (2 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)